American Century Companies’s Anika Therapeutics ANIK Stock Holding History

American Century Companies’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.52M	Sell	103,559 -34,025	-25%	-$504K	﹤0.01%	2291
2026 Q1	$1.99M	Buy	137,584 +37,263	+37%	+$433K	﹤0.01%	2118
2025 Q4	$964K	Buy	100,321 +42,176	+73%	+$404K	﹤0.01%	2329
2025 Q3	$547K	Buy	58,145 +13,984	+32%	+$134K	﹤0.01%	2485
2025 Q2	$467K	Buy	44,161 +10,909	+33%	+$138K	﹤0.01%	2543
2025 Q1	$500K	Buy	33,252 +3,361	+11%	+$55.9K	﹤0.01%	2510
2024 Q4	$492K	Buy	29,891 +2,553	+9%	+$50.4K	﹤0.01%	2510
2024 Q3	$675K	Buy	27,338 +3,446	+14%	+$89.3K	﹤0.01%	2372
2024 Q2	$605K	Buy	23,892 +2,518	+12%	+$65.3K	﹤0.01%	2370
2024 Q1	$543K	Buy	21,374 +5,715	+36%	+$138K	﹤0.01%	2424
2023 Q4	$355K	Buy	15,659 +4,127	+36%	+$85.4K	﹤0.01%	2495
2023 Q3	$215K	Buy	11,532 +2,595	+29%	+$53.8K	﹤0.01%	2570
2023 Q2	$232K	Buy	+8,937	New	+$239K	﹤0.01%	2486
2020 Q3	–	Sell	-11,007	Closed	-$415K	–	1805
2020 Q2	$415K	Sell	11,007 -7,146	-39%	-$235K	﹤0.01%	1341
2020 Q1	$525K	Buy	18,153 +93	+0.5%	+$3.76K	﹤0.01%	1151
2019 Q4	$936K	Sell	18,060 -34,898	-66%	-$2.03M	﹤0.01%	1098
2019 Q3	$2.91M	Sell	52,958 -15,050	-22%	-$773K	﹤0.01%	906
2019 Q2	$2.76M	Buy	68,008 +36,727	+117%	+$1.34M	﹤0.01%	971
2019 Q1	$946K	Buy	+31,281	New	+$1.07M	﹤0.01%	1065
2018 Q4	–	Sell	-15,039	Closed	-$634K	–	1233
2018 Q3	$634K	Hold	15,039	–	–	﹤0.01%	1152
2018 Q2	$481K	Buy	15,039 +10,068	+203%	+$415K	﹤0.01%	1193
2018 Q1	$247K	Buy	+4,971	New	+$281K	﹤0.01%	1213
2016 Q3	–	Sell	-35,125	Closed	-$1.88M	–	1327
2016 Q2	$1.88M	Sell	35,125 -18,688	-35%	-$881K	﹤0.01%	1039
2016 Q1	$2.41M	Buy	53,813 +2,296	+4%	+$93.1K	﹤0.01%	965
2015 Q4	$1.97M	Buy	51,517 +411	+0.8%	+$15.7K	﹤0.01%	1020
2015 Q3	$1.63M	Sell	51,106 -38,316	-43%	-$1.34M	﹤0.01%	1041
2015 Q2	$2.95M	Sell	89,422 -14,775	-14%	-$527K	﹤0.01%	977
2015 Q1	$4.29M	Sell	104,197 -809	-0.8%	-$32.7K	﹤0.01%	885
2014 Q4	$4.28M	Buy	105,006 +18	+0%	+$704	﹤0.01%	903
2014 Q3	$3.85M	Buy	104,988 +18,864	+22%	+$815K	﹤0.01%	941
2014 Q2	$3.99M	Buy	86,124 +8,229	+11%	+$366K	﹤0.01%	959
2014 Q1	$3.2M	Sell	77,895 -29,591	-28%	-$1.1M	﹤0.01%	1027
2013 Q4	$4.1M	Buy	107,486 +35,801	+50%	+$1.1M	﹤0.01%	958
2013 Q3	$1.72M	Buy	71,685 +21,011	+41%	+$472K	﹤0.01%	1128
2013 Q2	$861K	Buy	+50,674	New	+$731K	﹤0.01%	1228

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies's ANIK Position: Q2 2026 in Review

American Century Companies reduced its Anika Therapeutics (ANIK) stake by 25% in Q2 2026, selling an estimated $504K and leaving 103,559 shares worth $1.52M. The position accounts for ﹤0.01% of the portfolio, ranked #2291.

American Century Companies first reported a position in ANIK in Q2 2013 and has held it in 35 quarters since. The position peaked at $4.29M in Q1 2015. 104 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

American Century Companies held 103,559 shares of Anika Therapeutics worth $1.52M as of Q2 2026.
American Century Companies sold 34,025 Anika Therapeutics shares in Q2 2026, an estimated $504K.
Anika Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #2291 holding.
American Century Companies first reported a position in Anika Therapeutics in Q2 2013 and has held it in 35 quarters since.
American Century Companies's Anika Therapeutics position peaked at $4.29M in Q1 2015.
104 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.